Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Humacyte Inc maintains a gross margin of 65.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3239.04%, while the net margin is -2325.37%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively HUMA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, HUMA competes directly with industry leaders such as RNAC and CGEN. With a market capitalization of $194.33M, it holds a leading position in the sector. When comparing efficiency, HUMA's gross margin of 65.47% stands against RNAC's 100.00% and CGEN's 12.74%. Such benchmarking helps identify whether Humacyte Inc is trading at a premium or discount relative to its financial performance.
